Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1155/2021/9987931 http://scihub22266oqcxt.onion/10.1155/2021/9987931 34423043!8376466!34423043     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Biomed+Res+Int 2021 ; 2021 (ä): 9987931 Nephropedia Template TP {{tp|p=34423043|t=2021. Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19 |pdf=|usr=}}{{34423043}} gab.com Text Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19 JO: Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=34423043 #FOAvip OBJECTIVE: Respiratory failure is the leading cause of mortality in COVID-19 patients, characterized by a generalized disbalance of inflammation. The aim of this study was to investigate the relationship between immune-inflammatory index and mortality in PSI IV-V patients with COVID-19. METHODS: We retrospectively reviewed the medical records of COVID-19 patients from Feb. to Apr. 2020 in the Zhongfa Xincheng Branch of Tongji Hospital, Wuhan, China. Patients who presented high severity of COVID-19-related pneumonia were enrolled for further analysis according to the Pneumonia Severity Index (PSI) tool. RESULTS: A total of 101 patients diagnosed with COVID-19 were identified at initial research. The survival analysis revealed that mortality of the PSI IV-V cohort was significantly higher than the PSI I-III group (p = 0.0003). The overall mortality in PSI IV-V patients was 32.1% (9/28). The fatal cases of the PSI IV-V group had a higher level of procalcitonin (p = 0.022) and neutrophil-to-lymphocyte ratio (p = 0.033) compared with the survivors. Procalcitonin was the most sensitive predictor of mortality for the severe COVID-19 population with area under receiver operating characteristic curve of 0.78, higher than the neutrophil-to-lymphocyte ratio (0.75) and total lymphocyte (0.68) and neutrophil (0.67) counts. CONCLUSION: Procalcitonin and neutrophil-to-lymphocyte ratio may potentially be effective predictors for mortality in PSI IV-V patients with COVID-19. Increased procalcitonin and neutrophil-to-lymphocyte ratio were associated with greater risk of mortality. Twit Text FOAVip Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19 ????Biomed Res Int http://www.kidney.de/pget.php?&tw=1&pmid=34423043 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34423043 #FOAvip English Wikipedia <ref>{{Cite pmid|34423043}}</ref> Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients with COVID-19 #MMPMID34423043 Han R; Su H; Guo G; Wang Q; Ma J; Li Z; Huang S; Ni Y; Hu R; Huang D; Zhou H Biomed Res Int 2021[]; 2021 (ä): 9987931 PMID34423043show ga OBJECTIVE: Respiratory failure is the leading cause of mortality in COVID-19 patients, characterized by a generalized disbalance of inflammation. The aim of this study was to investigate the relationship between immune-inflammatory index and mortality in PSI IV-V patients with COVID-19. METHODS: We retrospectively reviewed the medical records of COVID-19 patients from Feb. to Apr. 2020 in the Zhongfa Xincheng Branch of Tongji Hospital, Wuhan, China. Patients who presented high severity of COVID-19-related pneumonia were enrolled for further analysis according to the Pneumonia Severity Index (PSI) tool. RESULTS: A total of 101 patients diagnosed with COVID-19 were identified at initial research. The survival analysis revealed that mortality of the PSI IV-V cohort was significantly higher than the PSI I-III group (p = 0.0003). The overall mortality in PSI IV-V patients was 32.1% (9/28). The fatal cases of the PSI IV-V group had a higher level of procalcitonin (p = 0.022) and neutrophil-to-lymphocyte ratio (p = 0.033) compared with the survivors. Procalcitonin was the most sensitive predictor of mortality for the severe COVID-19 population with area under receiver operating characteristic curve of 0.78, higher than the neutrophil-to-lymphocyte ratio (0.75) and total lymphocyte (0.68) and neutrophil (0.67) counts. CONCLUSION: Procalcitonin and neutrophil-to-lymphocyte ratio may potentially be effective predictors for mortality in PSI IV-V patients with COVID-19. Increased procalcitonin and neutrophil-to-lymphocyte ratio were associated with greater risk of mortality. |*Pandemics[MESH] |*SARS-CoV-2[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |Biomarkers/blood[MESH] |COVID-19/*immunology/mortality/*physiopathology[MESH] |China/epidemiology[MESH] |Cohort Studies[MESH] |Female[MESH] |Humans[MESH] |Inflammation/immunology/physiopathology[MESH] |Lymphocytes/immunology[MESH] |Male[MESH] |Middle Aged[MESH] |Neutrophils/immunology[MESH] |Pneumonia, Viral/immunology/mortality/physiopathology[MESH] |Procalcitonin/blood[MESH] |Prognosis[MESH] |Retrospective Studies[MESH] |Risk Factors[MESH] |Severity of Illness Index[MESH]Prognostic Value of Immune-Inflammatory Index in PSI IV-V Patients wit(epmc).pdf DeepDyve Pubget Overpricing